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Basal Laminar Drusen Caused by Compound
Heterozygous Variants in the CFH Gene
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Sander B. Nabuurs,3 Ellen Blokland,2 Frans P.M. Cremers,2 and Anneke I. den Hollander2,*
Age-related macular degeneration (AMD) is a multifactorial disease that is strongly associated with the Tyr402His variant in the comple-
ment factor H (CFH) gene. Drusen are hallmark lesions of AMD and consist of focal-inﬂammatory and/or immune-mediated depositions
of extracellular material at the interface of the retinal pigment epithelium (RPE) and the Bruchmembrane. We evaluated the role of CFH
in 30 probands with early-onset drusen and identiﬁed heterozygous nonsense, missense, and splice variants in ﬁve families. The affected
individuals all carried the Tyr402His AMD risk variant on the other allele. This supports an autosomal-recessive disease model in which
individuals who carry a CFHmutation on one allele and the Tyr402His variant on the other allele develop drusen. Our ﬁndings strongly
suggest that monogenic inheritance of CFH variants can result in basal laminar drusen in young adults, and this can progress to
maculopathy and severe vision loss later in life.Age-related macular degeneration (AMD) (MIM 603075) is
the most common cause of blindness in the Western
world, with a prevalence of 12% after 80 years of age.1
The presence of macular and/or extramacular drusen is
an important risk factor for the development of advanced
AMD.2 Different clinical subtypes of drusen have been
described, but all drusen appear to be similar on the level
of ultrastructural and molecular composition.3 AMD is
a multifactorial disorder, and variants in several genes
have been shown to be associated with the disease.1,4
Strong association is seen with the Tyr402His variant and
several noncoding variants in the complement factor H
(CFH) gene (MIM 134370).5–9 The CFH protein has been
detected in drusen and acts as an inhibitor of the alterna-
tive complement cascade.10
‘‘Basal laminar drusen’’ (also termed ‘‘cuticular drusen’’
or ‘‘early adult onset, grouped drusen’’) refers to an early-
onset-drusen phenotype that shows a pattern of uniform
small (25 to 75 mm), slightly raised, yellow subretinal nod-
ules randomly scattered in the macula. The term ‘‘basal
laminar drusen’’ is widely used but may be considered
a misnomer because these deposits do not appear to corre-
spond with nodular or diffuse thickenings of the Bruch
membrane.3 In later stages, these drusen often become
more numerous, with clustered groups of drusen scattered
throughout the retina. On ﬂuorescein angiography, a typi-
cal ‘‘stars-in-the-sky’’ picture may be observed (Figure 1).11
In time, these small basal laminar drusen may expand and
ultimately lead to a serous pigment epithelial detachment
of the macula, which may result in visual loss.11 The basal-
laminar-drusen phenotype has an even stronger associa-
tion with the Tyr402His variant than AMD, with an allele
frequency of 70%, compared to 55% in a cohort of typical
AMD patients and 34% in controls.12 Basal laminar drusen516 The American Journal of Human Genetics 82, 516–523, Februaryare also seen in patients with membranoproliferative glo-
merulonephritis type II (MPGN-II, MIM 609814), a severe
early-onset renal disease caused by an uncontrolled sys-
temic activation of the alternative pathway of the com-
plement cascade, which can be caused by highly penetrant
recessive mutations in the CFH gene.13,14 MPGN-II associ-
ated drusen appear to be morphologically and composi-
tionally similar to drusen in AMD.15 Mutations in CFH
have also been associated with atypical hemolytic uremic
syndrome (aHUS, MIM 235400), a severe disease fre-
quently leading to end-stage renal failure.16,17
In this study, we evaluated 30 probands diagnosed with
basal-laminar-drusen maculopathy. At early stages, the
diagnosis was based on the observation of small yellow-
white deposits (‘‘basal laminar drusen’’ or ‘‘cuticular dru-
sen’’) in the macula, sometimes extending toward the
(mid-) peripheral retina, in combination with a ‘‘stars-in-
the-sky’’ appearance on ﬂuorescein angiography (Figure 1).
The occurrence of conﬂuent (‘‘soft’’) drusen of variable size
in the central macular region and the subsequent develop-
ment of a serous detachment of the retina and/or retinal
pigment epithelium (RPE) were considered typical for the
later stages of this disorder. A ﬁnal feature in the later stages
is the geographic atrophy of the RPE that is frequently ob-
served after resolution of the detachment. An overview of
the clinical characteristics of these patients is given in Ta-
bles 1 and 2. Four patients did not experience visual com-
plaints prior to the diagnosis (the ﬁnding of retinal abnor-
malities was coincidental), whereas 26 patients had
noticed a decrease in visual acuity, with an age at onset
ranging from 35 to 70 yr (mean, 50 yr). Eight patients re-
ported family members with macular disease or visual dis-
turbances compatible with macular disease. In 12 patients
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retina. In 28 patients (93%), the development of large, ex-
udative drusen could be observed in the central macular
area. A pseudovitelliform, yellow, serous retinal or RPE de-
tachment of the central macula with associated loss of vi-
sual acuity was seen in eight patients (27%). Ten patients
(33%) showed chorioretinal atrophy of themacula. During
ﬂuorescein angiography, individual drusen as well as the
larger exudative drusen were hyperﬂuorescent. Choroidal
neovascularization was seen in eight eyes of ﬁve patients.
We evaluated the role of CFH in the 30 probands by
sequence analysis of the 22 coding exons and splice junc-
tions. The Tyr402His variant was present in 48% of CFH al-
leles (Tables 1 and 2), which is lower than the 70% reported
elsewhere in patients with basal laminar drusen,12 but
higher than in healthy control subjects (34%). More
importantly, we found that seven patients in two families
(A and B) were compound heterozygous for the nonsense
mutation Gln408X and the AMD risk allele Tyr402His (Fig-
ure 2). The CFH variants in the deceased individual A-II.3
were deduced upon CA-marker analysis in the right branch
of family A. Clinical characteristics of affected familymem-
bers are shown in Figure 3 and Table 2. Two family mem-
bers (A-IV.1 and A-IV.2) carrying only the Gln408X allele
did not develop drusen.
In a third family (C), we identiﬁed three individuals
with drusen who carried a heterozygous variant
(Arg1078Ser) on one allele and the Tyr402His variant on
the other allele (Figure 2). The Arg1078Ser variant occurs
in the 18th short consensus repeat (SCR18) of CFH. To pre-
dict the effect of this variant, we constructed a homology
model for SCR18 (Figure 4). Because SCR18 shares 40% ho-
mology with SCR19, model building was straightforward
with the SCR19-20 structure used as a template.18 The
Figure 1. Fluorescein Angiogram of the Basal-Laminar Drusen
Phenotype
Typical fluorescein angiogram of a patient with advanced drusen
maculopathy resembling basal laminar drusen (patient 9). Note
the typical ‘‘stars-in-the-sky’’ appearance, with central confluence
of drusen and the small pseudovitelliform pigment epithelial
detachment.The Amemodel shows that Arg1078 is solvent exposed, and the
change to serine at this position is not expected to have
a large structural effect on SCR18 itself. However, SCR18
neighbors the C-terminal SCR domains 19 and 20, which
were shown to have many different interaction partners,
including the major opsonin C3b, glycosaminoglycans,
and endothelial cells. The Arg1078Ser variant introduces
a smaller side chain in SCR18 and abolishes the negative
charge at this position. This change might interfere
with the different interactions in which CFH participates.
Notably, mutation of a nearby residue (Gln1076Glu) was
identiﬁed in a patient with aHUS (FH aHUS mutation
database).
In patient D, we identiﬁed the Tyr402His variant homo-
zygously, and a heterozygous variant was identiﬁed in the
splice-donor site of exon 3 (c.350þ6T/G) (Figure 2). This
variant is predicted to severely affect splicing, given that
the splice prediction score is reduced from 0.97 to 0.59
(NNSPLICE version 0.9).19 Moreover, this residue is com-
pletely conserved between human and all species for
which the genomic sequence of CFH is available (rhesus
macaque, mouse, rat, dog, horse, opossum, platypus, and
elephant). The deceased mother of patient D was diag-
nosed with macular and peripheral drusen by a local
ophthalmologist at the age of 43.
A patient in a ﬁfth family (E) carried a heterozygous
amino acid variant (Arg567Gly) and was heterozygous
for the Tyr402His variant (Figure 2). Other family mem-
bers were unavailable for examination or segregation
analysis. The Arg567Gly variant occurs in the interdo-
main hinge region between the short consensus repeats
SCR9 and SCR10. Because no experimental structure of
SCR 9-10 is known, we built a homology model of this
hinge region and the two surrounding domains by using
the crystal structure of the CFH SCR domains 19-20 as
a template.18 In our model, Arg567 is located on the pro-
tein surface, and hydrogen bonds from the hinge region
to the backbone of SCR10 (Figure 4). As such, Arg567
could play a structural role in deﬁning the orientation
of SCR9 with respect to SCR10. This hypothesis is sup-
ported by Glu566 and Glu568, which hydrogen bond to
a tyrosine residue in SCR9 and SCR10, respectively. Given
that the charged Arg567 in our model also appears to be
partially exposed to the surface, it could play a role in
one of the many interactions in which CFH can engage.
For example, CFH has been shown to bind complement
factor C3b via interaction sites in SCR domains 1–4, 9,
12–14, 19, and 20.20,21 Furthermore, CFH can bind
C-reactive protein (CRP) via SCR7 but also in the region
spanning SCR8-11.22 This would place Arg567 close to
a C3b-binding site and in a CRP-binding region. Arg567-
Gly removes a positive charge in the interdomain hinge
region between SCR9 and SCR10, and is likely to result
in an increased mobility of the linker between these re-
peats. On the basis of these ﬁndings, we speculate that
Arg567Gly might result in an altered afﬁnity of CFH for
C3b and possibly also CRP.rican Journal of Human Genetics 82, 516–523, February 2008 517
Table 1. Clinical Characteristics of Drusen Patients without Compound Heterozygous CFH Mutations
Patient
Number Sex
Family
Historya
Age at
Onsetb Age
Visual Acuityc
Retinal Phenotyped,e
CFH
Variants
CFH
Tyr402HisOD OS
1 F no - 53 20/20 20/20 ODS: extensive macular drusen - Tyr/Tyr
2 F no - 40 20/20 20/20 ODS: extensive confluent macular drusen - Tyr/His
3 F no 53 54 20/70 20/50 ODS: numerous small drusen in posterior pole - Tyr/His
4 M no 51 57 20/70 20/70 ODS: macula: confluent drusen surrounded by
small drusen, PED, chorioretinal atrophy,
many small drusen in peripheral retina
- Tyr/His
5 F no 49 50 20/32 20/70 ODS: extensive confluent and atrophic drusen
of the posterior pole, PED, OD: occult CNV,
OS: minimally classic CNV
- His/His
6 F no 35 35 20/20 20/20 ODS: many drusen throughout (mid-)
peripheral retina, confluent drusen in
posterior pole
- Tyr/Tyr
7 F yes 44 47 20/32 20/32 OD: confluent drusen with large exudative
PED and large occult exudative CNV, OS: large
confluent drusen with surrounding small
drusen
- Tyr/His
8 M no 45 58 20/25 20/100 ODS confluent macular drusen and
chorioretinal atrophy
- Tyr/His
9 F no 43 46 20/25 20/25 ODS confluent macular drusen, PED (Figure 1) - Tyr/His
10 F no 43 57 20/125 20/200 ODS: very extensive atrophic, confluent
macular drusen and (mid-) peripheral drusen,
OD: chorioretinal atrophy, exudative CNV
OS: fibrotic scar
- Tyr/His
11 F no 53 54 20/20 20/25 ODS: confluent macular drusen, small
midperipheral drusen
- Tyr/His
12 M no 50 54 20/32 20/20 ODS: confluent macular drusen, small
midperipheral drusen
- Tyr/His
13 M no 48 60 20/32 20/250 ODS: confluent macular drusen, PED - Tyr/His
14 F no 57 57 20/32 20/25 ODS: extensive confluent macular drusen,
pseudovitelliform PED
- Tyr/His
15 M no 70 74 20/25 20/25 ODS: confluent macular drusen - Tyr/Tyr
16 F no 43 56 20/20 20/20 ODS: extensive drusen in posterior pole,
confluent macular drusen
- Tyr/His
17 F no 44 44 20/25 20/100 ODS: extensive drusen in posterior pole,
confluent macular drusen
- His/His
18 M no 56 58 20/25 20/160 OD: confluent macular drusen, OS: macular
drusen, large pseudovitelliform PED
- Tyr/His
19 F no 43 43 20/25 20/100 ODS: confluent macular drusen - Tyr/His
20 F no - 38 20/20 20/20 ODS: large confluent drusen in posterior pole
and midperipheral retina, macular
pigmentary changes
- Tyr/His
21 F yes 51 51 20/40 20/2000 ODS: extensive macular and (mid-) peripheral
drusen, confluent macular drusen and
chorioretinal atrophy
- Tyr/His
22 F no - 69 20/20 20/20 ODS: confluent macular drusen with
parafoveal chorioretinal atrophy
- Tyr/His
23 F no 47 48 20/80 20/80 (A) ODS: extensive confluent macular drusen,
numerous small (mid-) peripheral drusen, OD:
large occult CNV
- Tyr/His
24 F yes 44 45 20/32 20/20 ODS: innumerable drusen throughout retina,
confluent macular drusen
Asn1050Tyr Tyr/His
25 F ? 62 63 20/50 20/30 ODS: confluent macular drusen and
geographic atrophy, innumerable (mid-)
peripheral drusen, patches of chorioretinal
atrophy, reticular pattern of
hyperpigmentation
Glu936Asp Tyr/His
a A positive family history was defined as reported family members with macular disease.
b ‘‘–’’ indicates no visual loss reported.
c ‘‘A’’ denotes amblyopia.
d ‘‘PED’’ denotes pigment epithelial detachment.
e ‘‘CNV’’ denotes choroidal neovascularization.518 The American Journal of Human Genetics 82, 516–523, February 2008
The new CFH variants identiﬁed in these families were
not identiﬁed in 92 ethnically matched control subjects,
nor in 90 controls between 65 and 85 years of age who
did not have any signs of maculopathy. In two other pa-The Ametients, we identiﬁed Asn1050Tyr and Glu936Asp heterozy-
gously. The Asn1050Tyr variant was previously found in
4% of control alleles,16 and the Glu936Asp variant was
found in 18% of controls.23 Although proband 24 in ourTable 2. Clinical Characteristics of Drusen Patients and Family Members Carrying Compound Heterozygous CFH Mutations
Patient
Codea Sex
Family
Historyb
Age at
Onsetc Age
Visual Acuityd
Retinal Phenotypee,f
CFH
Variant
CFH
Tyr402HisOD OS
A-III.5 (P) M yes 45 62 20/400 20/25 OD: confluent macular drusen, chorioretinal
atrophy, (mid-) peripheral retina: cystoid
drusen, chorioretinal atrophy (Figure 3A,B)
OS: confluent macular drusen, (mid-)
peripheral retina: cystoid drusen,
chorioretinal atrophy (Figure 3C,D)
Gln408X Tyr/His
A-II.3 M yes ? deceased 20/25 20/200 ODS: extensive confluent drusen and
chorioretinal atrophy
Gln408X Tyr/His
A-III.1 F yes 63 83 20/800 20/800 ODS: chorioretinal atrophy of posterior pole,
large atrophic drusen, subretinal fibrosis,
extensive drusen in atrophic (mid-)
peripheral retina
Gln408X Tyr/His
A-III.3 M yes 67 81 20/50 20/400 ODS: confluent atrophic macular drusen and
chorioretinal atrophy, extensive drusen in
(mid-) peripheral retina
Gln408X Tyr/His
A-IV.1 F yes - 50 20/20 20/20 ODS: normal Gln408X Tyr/Tyr
A-IV.2 F yes - 48 20/20 20/20 ODS: normal Gln408X Tyr/Tyr
B-II.1 (P) M yes 48 51 20/25 20/25 ODS: confluent macular drusen, (mid-)
peripheral retina: small drusen and discrete
pigmentary changes (Figure 4E-H)
Gln408X Tyr/His
B-I.2 F yes 68 85 20/400 20/32 ODS: confluent macular drusen and
chorioretinal atrophy, (mid-) peripheral
retina: small drusen and discrete pigmentary
changes
Gln408X Tyr/Tyr
B-III.1 M yes - 25 20/20 20/20 ODS: very discrete midperipheral cystoid
drusen, clearly visualized on fluorescein
angiography
Gln408X Tyr/His
B-III.2 M yes - 22 20/20 20/20 ODS: barely discernable macular and
peripheral drusen, clearly visualized on
fluorescein angiography (Figure 4I,J)
Gln408X Tyr/His
C-II.2 (P) M yes 57 65 20/40 20/200 ODS: innumerable small drusen throughout
retina, (mid-) peripheral chorioretinal
atrophy and reticular pattern of
hyperpigmentation, OD: large confluent
macular drusen, PED, occult CNV,
chorioretinal atrophy, OS: atrophic scar in
macula, surrounded by large confluent
drusen
Arg1078Ser Tyr/His
C-II.3 F yes - 64 20/25 20/25 ODS: confluent macular drusen and PED,
numerous small drusen in (mid-) peripheral
retina
Arg1078Ser Tyr/His
C-II.5 M yes - 56 20/16 20/16 ODS: barely discernable (mid-) peripheral
drusen, clearly visualized on fluorescien
angiography
Arg1078Ser Tyr/His
D M yes 54 54 20/20 20/125 (A) ODS: large confluent macular drusen, cystoid
drusen in midperipheral retina
c.350þ6T/G His/His
E F yes (aunt) 54 55 20/32 20/70 ODS: confluent macular drusen surrounded by
small drusen, PED, chorioretinal atrophy,
small drusen in peripheral retina
Arg567Gly Tyr/His
a ‘‘P’’ denotes proband.
b A positive family history was defined as reported family members with macular disease.
c ‘‘–’’ indicates no visual loss reported.
d ‘‘A’’ denotes amblyopia.
e ‘‘CNV’’ denotes choroidal neovascularization.
f ‘‘PED’’ denotes pigment epithelial detachment.rican Journal of Human Genetics 82, 516–523, February 2008 519
study was compound heterozygous for the Asn1050Tyr
and Tyr402His alleles, his affected father carried the
Asn1050Tyr variant without Tyr402His, indicating that
compound heterozygosity of CFH variants does not cause
the disease in this family.
Previous studies have shown that the Tyr402His variant
in CFH is strongly associated with AMD and basal laminar
drusen.5–7,12 Our ﬁndings strongly support a recessive-
disease model in a subgroup of patients with basal laminar
drusen. In these families, individuals develop drusen when
they carry a CFHmutation on one allele and the Tyr402His520 The American Journal of Human Genetics 82, 516–523, Februaryvariant on the other allele. The presence of aCFHmutation
in the absence of the Tyr402His variant, however, might
contribute to the development of AMD at later age (e.g.,
in individual B-I.2). Compound heterozygosity was con-
ﬁrmed in four families (A, B, C, and D), but in one family
(E) segregation analysis could not be performed. Affected
individuals of families A, B, C, and D presented with
many small drusen with a slightly pigmented border pe-
ripheral to the vascular arcades. These peculiar drusen
were most readily observed on ophthalmoscopy, ﬂuores-
cein angiography, and infrared reﬂectance photographyFigure 2. Molecular Genetic Analysis of the CFH Gene in Families Affected with Drusen Maculopathy
(A and B) Seven affected individuals in two families are compound heterozygous for the nonsense mutation Gln408X and the AMD risk
allele Tyr402His. Brackets flanking the CFH variants of A-I.3 indicate that they were deduced through CA-marker analysis.
(C) Three affected individuals in a third family are compound heterozygous for the missense variant Arg1078Ser and Tyr402His.
(D) Patient D is homozygous for the Tyr402His variant, and in addition, he carries a heterozygous variant in the splice-donor site of exon 3
(c.350þ6T/G).
(E) A patient in a fifth family carries a heterozygous amino acid variant (Arg567Gly) and is heterozygous for the Tyr402His variant.
Segregation analysis could not be performed.
Grey pedigree symbols denote patients with basal laminar drusen. The black symbols denote two females affected with AMD. Numbers in
the pedigree symbols reflect current age.
(F) Sequences of heterozygous variants detected in the CFH gene.2008
(Figures 3C, 3D, and 3J). Optical coherence tomography
(OCT) showed that the appearance of the drusen periph-
eral to the vascular arcades was similar to that of the drusen
located at the macula.
Mutations in the CFH gene can cause severe renal failure
in patients with MPGN-II and aHUS. We did not observe
signs of a renal disorder with routine laboratory testing
of blood and urine in the drusen patients with compound
heterozygous CFH variants. It is possible that in these pa-The Ametients, the residual CFH activity sustains sufﬁcient comple-
ment regulatory activity for normal renal function,
whereas the ocular environment may be more sensitive
to deposition and damage. Subclinical renal abnormalities,
however, remain possible.24
Therearea fewexamples inwhichheterozygosity foramu-
tation implicated in aMendelian disorder appeared to result
in an increased risk for a complex disease.25 In this study, we
show thatmonogenic inheritance ofCFH variants can resultFigure 3. Retinal Phenotypes of Drusen
Patients Carrying the Combination of
a Gln408X Mutation and the Tyr402His
AMD Risk Variant
(A–D) Retinal phenotype of patient A-
III.5. (A) Fundus photograph of the right
eye, showing extensive chorioretinal atro-
phy of the posterior pole. At the first exam-
ination, 17 years earlier, these areas corre-
sponded with large confluent drusen with
incipient atrophy. (B) The short-wave-
length fundus autofluorescence (FAF) im-
age shows an absence of FAF corresponding
with the patches of chorioretinal atrophy,
not only in the macular area but also in
the midperipheral retina. Moreover, diffuse
changes in FAF intensity can be observed.
(C) Fundus photograph of the left eye,
showing large confluent drusen and mild
chorioretinal atrophy. (D) An infrared re-
flectance photograph clearly visualizes
small, round, midperipheral drusen scat-
tered between the patches of chorioretinal
atrophy. The drusen seen with infrared
reflectance corresponded with the discrete,
round, yellow-white drusen with a slightly
pigmented border seen on ophthalmos-
copy.
(E–H) Retinal phenotype of patient B-II.1.
(E) Fundus photograph showing confluent
macular drusen. (F) The macular drusen
can be more easily detected on the fluores-
cein angiogram. (G) Optical coherence
tomography (OCT, oblique section) show-
ing small dome-shaped elevations of the
‘‘outer red line,’’ which correspond with
the visible drusen on ophthalmoscopy (ar-
row). (H) Similar to patient A-III.5, small
midperipheral drusen were seen in this
patient, and OCT revealed aspects similar
to the macular drusen.
(I and J) Fluorescein angiography showed
tiny hyperfluorescent drusen in the parafo-
veal area and in the (mid-) peripheral ret-
ina of Patient B-III.2 (the 22-year-old
asymptomatic son of patient B-II.1), but
the drusen were difficult to discern on
ophthalmoscopy. His 25-year-old brother
(B-III.1) had similar midperipheral le-
sions, but to a lesser extent.rican Journal of Human Genetics 82, 516–523, February 2008 521
in basal laminar drusen in young adults, and this can prog-
ress to maculopathy and severe vision loss later in life. Our
ﬁndings indicate that basal laminar drusenandAMDbelong
to a spectrum of diseases associated with either monogenic
or multifactorial inheritance of variants in the CFH gene.
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Figure 4. Molecular Modeling of Missense Variants Detected
in CFH
(A and B) Model of the SCR18 domain, depicting the effect of
the Arg1078Ser variant. (A) wild-type sequence (Arg1078). (B)
Arg1078Ser variant.
(C andD)Model of the SCR9andSCR10domains, depicting theeffect of
the Arg567Gly variant. (C) wild-type sequence (Arg567). (D) Arg567-
Gly variant. The SCR9 domain is shown in yellow, the SCR10 domain in
orange, and the linker region between the two domains is shown in
blue. Hydrogen-bonding partners for the residues in the linker region
are indicated with dotted lines. All figures were made with Yasara.522 The American Journal of Human Genetics 82, 516–523, FebruaryOnline Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.
gov/Omim/
Yasara, http://www.yasara.orgReferences
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